1
Pharmaco- genomics: The Search for Individualized Therapies Edited by Julio Licinio and Ma-Li Wong, Wiley, 2002, Price 74.30, 600 pages in hardback, ISBN 3-527-30380-4 Coincident with the publication of the nucleotide sequence of the human genome and advances in sequencing and genotyping technologies, the emerging field of pharmacogenomics has received significant attention. This attention has come from scientists engaged in the discovery and development of therapeutics, physicians dedicated to treating individual patients and, increasingly, from a treatment conscious public. As such, a book about this rapidly evolving field, which sets out the current thinking on its use and applications in the creation of new medicines, is timely and welcome. Pharmacogenomics: The Search for Individualized Therapies is composed of chapters written by some of the world’s leading academic and corporate experts. It provides a timely overview of the field, applications both achieved and hoped for, and challenges for application in the real world of clinical practice. It is written primarily to scientists and students so it is no surprise that it is compiled much like a course textbook, beginning with introductory chapters covering the history, current state and future potential of pharmacogenomics. The format is helpful, each chapter beginning with an abstract and ending with a summary of conclusions and a comprehensive reference list. Because the last two thirds of the book are dedicated to exploring the pharmacogenomics of specific classes of therapeutics, diseases or conditions, the references provide a valuable compilation for the scientist interested in a particular therapeutic area. As noted, the first third of the book focuses broadly on the state and future of pharmacogenomics. Many of these chapters attempt to define pharmacogenomics and to distinguish it from the older term, pharmacogenetics. The reader looking for consensus here will be disappointed and will find many conflicting and overlapping perspectives. As the editors state in their preface, these contradictory and repetitive paragraphs are intentionally left unedited to present the author’s individual opinions. Although difficult for the reader, it accurately represents the current state of the developing field. Interesting, in his chapter The Role of Pharmacogenetics in Drug Discovery and Therapeutics, Klaus Lindpaintner makes a compelling presentation of what he believes is an emerging consensus on the differences between the two terms and their use. The broad opening chapter on the promise and limitations of pharmacogenomics is one that most readers who are familiar with the field will find a recapitulation of the numerous articles already written on the subject. Each of the subsequent chapters comprising the introductory third of the book focus on the history and outcomes of sequencing the human genome, its relevance to discovering and establishing the clinical validity of pharmacogenomic markers, their roles in understanding the action of drugs, and how they might be applied in the pharmaceutical processes of drug design and development. These first seven chapters provide the reader with a good review of the various strategies employed to discover pharmacogenomic markers, validate their use through appropriately designed and powered association studies, and the current thinking on their application in drug research and development. The remainder of the book explores the state of knowledge of pharmacogenomics in specific classes of drug targets, transporters, therapeutic agents and disease states. These chapters are well researched and written by leading experts in the field. They provide useful reviews of how genetics is being employed in specific therapeutic areas and, taken together, indicate those areas that are most likely to benefit soon from a genetic approach. Although much, if not all, of the same information can be found in journals specific to the respective field, it is useful to have them referenced in specific chapters and to have the commentary and perspective of the various expert authors. In attempting to review the state-of-the-art of an emerging and rapidly changing field, the editors can only provide ‘a snapshot in time’ of pharmacogenomics: it could soon be out-dated. However, the book does an excellent job of compiling a current picture of an important and compelling field of medical research. Ronald Norton VP, Operations DNA Sciences 3500 Paramount Parkway Morrisville, NC 27560, USA e-mail: [email protected] DDT Vol. 7, No. 21 November 2002 update book review 1359-6446/02/$ – see front matter ©2002 Elsevier Science Ltd. All rights reserved. PII: S1359-6446(02)02401-7 1085 www.drugdiscoverytoday.com BioMedNet Reviews 5000+ review articles including Trends, Current Opinion and DDT Bookmark: http://reviews.bmn.com/

Pharmacogenomics: The Search for Individualized Therapies

Embed Size (px)

Citation preview

Page 1: Pharmacogenomics: The Search for Individualized Therapies

Pharmaco-genomics:The SearchforIndividualizedTherapies

Edited by Julio Licinioand Ma-Li Wong, Wiley, 2002, Price €74.30,600 pages in hardback, ISBN 3-527-30380-4

Coincident with the publication of thenucleotide sequence of the humangenome and advances in sequencingand genotyping technologies, theemerging field of pharmacogenomicshas received significant attention. Thisattention has come from scientistsengaged in the discovery anddevelopment of therapeutics, physiciansdedicated to treating individual patientsand, increasingly, from a treatmentconscious public. As such, a book aboutthis rapidly evolving field, which sets outthe current thinking on its use andapplications in the creation of newmedicines, is timely and welcome.

Pharmacogenomics: The Search forIndividualized Therapies is composed ofchapters written by some of the world’sleading academic and corporate experts.It provides a timely overview of the field,applications both achieved and hopedfor, and challenges for application in thereal world of clinical practice. It is writtenprimarily to scientists and students so it isno surprise that it is compiled much likea course textbook, beginning withintroductory chapters covering thehistory, current state and future potentialof pharmacogenomics. The format ishelpful, each chapter beginning with anabstract and ending with a summary ofconclusions and a comprehensivereference list. Because the last two thirdsof the book are dedicated to exploringthe pharmacogenomics of specific classesof therapeutics, diseases or conditions,the references provide a valuable

compilation for the scientist interested ina particular therapeutic area.

As noted, the first third of the book focuses broadly on the state andfuture of pharmacogenomics. Many ofthese chapters attempt to definepharmacogenomics and to distinguish itfrom the older term, pharmacogenetics.The reader looking for consensus herewill be disappointed and will find manyconflicting and overlapping perspectives.As the editors state in their preface,these contradictory and repetitiveparagraphs are intentionally leftunedited to present the author’sindividual opinions. Although difficult for the reader, it accurately representsthe current state of the developing field.Interesting, in his chapter The Role ofPharmacogenetics in Drug Discovery andTherapeutics, Klaus Lindpaintner makes a compelling presentation of what hebelieves is an emerging consensus onthe differences between the two termsand their use.

The broad opening chapter on the promise and limitations ofpharmacogenomics is one that mostreaders who are familiar with the fieldwill find a recapitulation of thenumerous articles already written on thesubject. Each of the subsequent chapterscomprising the introductory third of thebook focus on the history and outcomesof sequencing the human genome, itsrelevance to discovering and establishingthe clinical validity of pharmacogenomicmarkers, their roles in understanding theaction of drugs, and how they might beapplied in the pharmaceutical processesof drug design and development. Thesefirst seven chapters provide the readerwith a good review of the variousstrategies employed to discoverpharmacogenomic markers, validatetheir use through appropriately designedand powered association studies, andthe current thinking on their applicationin drug research and development.

The remainder of the book explores thestate of knowledge of pharmacogenomics

in specific classes of drug targets,transporters, therapeutic agents anddisease states. These chapters are wellresearched and written by leadingexperts in the field. They provide usefulreviews of how genetics is beingemployed in specific therapeutic areasand, taken together, indicate those areasthat are most likely to benefit soon froma genetic approach. Although much, ifnot all, of the same information can be found in journals specific to therespective field, it is useful to have themreferenced in specific chapters and tohave the commentary and perspectiveof the various expert authors.

In attempting to review thestate-of-the-art of an emerging andrapidly changing field, the editors canonly provide ‘a snapshot in time’ ofpharmacogenomics: it could soon beout-dated. However, the book does anexcellent job of compiling a currentpicture of an important and compellingfield of medical research.

Ronald NortonVP, OperationsDNA Sciences

3500 Paramount ParkwayMorrisville, NC 27560, USA

e-mail: [email protected]

DDT Vol. 7, No. 21 November 2002 updatebook review

1359-6446/02/$ – see front matter ©2002 Elsevier Science Ltd. All rights reserved. PII: S1359-6446(02)02401-7 1085www.drugdiscoverytoday.com

BioMedNet Reviews

5000+ review articles

including

Trends, Current Opinion

and DDT

Bookmark:

http://reviews.bmn.com/